Medtronic completed its acquisition of CathWorks for $585 million plus potential earn-out payments. The deal brings the AI-driven, wire-free FFRangio System into Medtronic's interventional cardiology portfolio after demonstrating non-inferiority to wire-based physiology in a 1,900-patient trial, and is expected to be neutral to accretive to earnings post-fiscal 2027.

Medtronic is identified as a key participant in the Middle East and Africa continuous glucose monitoring market, which is projected to expand from $320 million in 2025 to $855 million by 2034 at an 11.5% CAGR. Growth drivers include rising diabetes prevalence, digital health integration and improved healthcare infrastructure, balanced against high device costs and limited reimbursement.